You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥控股(01099.HK)年度純利升7.14%至62.525億元 末期息0.6元
格隆匯 03-30 06:16

格隆匯3月30日丨國藥控股(01099.HK)公佈,截至2019年12月31日止年度,公司實現營業收入人民幣4252.73億元,同比增加23.44%;實現溢利人民幣106.2億元,同比增長12.93%;母公司持有者應占溢利人民幣62.525億元,同比增長7.14%;每股盈利人民幣2.11元,末期股息每股人民幣0.60元(含税)。

收入增長主要由於集團醫藥分銷業務、醫藥零售業務及醫療器械業務收入的增長,且集團收入增長超過中國醫藥市場發展的平均水平。截至2018年及2019年12月31日止12個月的毛利率分別為9.06%及8.83%。

報告期間醫藥分銷收入增加20.02%,主要是由於集團醫藥分銷業務發展勢態良好及分銷網絡進一步擴展;醫藥零售收入增加33.77%,增長主要是由於零售藥品市場增長與集團零售藥店的網絡擴展;醫療器械收入增加40.06%,增長主要是由於集團醫療器械業務的收購擴張及業務增長。

未來,流通行業的結構性調整的影響會陸續顯現,集團作為醫藥流通行業的龍頭企業將認真研究行業動態,優化集團的主營業務,準確分析,主動應對,充分挖掘集團的核心競爭優勢,強化集團的多元化業務佈局,着力發展一站式、一體化的供應鏈服務能力,促進與上游製造業及下游終端客户的共贏發展。此外,集團還將在醫藥零售和醫療器械等業務領域篩選合適的併購目標,通過內生和外延增長的雙輪驅動,積極推動公司業務整體優化完善,盡全力減少行業政策帶來的負面影響,充分發掘新的利潤增長點,全面提升公司業務優勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account